Company intelligence / Profile preview
Chengdu Xilingyuan Pharmaceutical Co., Ltd.
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
Overview
Xiling Lab has advanced its lead ADC candidate SMP‑656 targeting HER2 into Phase 1 clinical trials for solid tumors. The company’s pipeline includes more than seven best-in-class or first-in-class drug conjugate programs with a focus on oncology. Preclinical data show strong efficacy and safety profiles for their leading assets. The company also develops high-end generics such as Eribulin Mesylate Injection with international regulatory filings.
- Therapeutic areas
- OncologyImmunologyGastroenterology
- Modalities
- Antibody-drug conjugates (ADCs)Small moleculesPeptide-drug conjugates (PDCs)Antibody-PROTACs (DACs)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Chengdu Xilingyuan Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Xilingyuan Pharmaceutical Co., Ltd..